BR112013022882A2 - uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários - Google Patents
uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratáriosInfo
- Publication number
- BR112013022882A2 BR112013022882A2 BR112013022882A BR112013022882A BR112013022882A2 BR 112013022882 A2 BR112013022882 A2 BR 112013022882A2 BR 112013022882 A BR112013022882 A BR 112013022882A BR 112013022882 A BR112013022882 A BR 112013022882A BR 112013022882 A2 BR112013022882 A2 BR 112013022882A2
- Authority
- BR
- Brazil
- Prior art keywords
- hormone
- treatment
- breast cancers
- receptor inhibitors
- egfr family
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 208000018819 hormone-resistant breast carcinoma Diseases 0.000 title 1
- 108091006082 receptor inhibitors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161451848P | 2011-03-11 | 2011-03-11 | |
| US201261604281P | 2012-02-28 | 2012-02-28 | |
| PCT/US2012/028792 WO2012125573A2 (en) | 2011-03-11 | 2012-03-12 | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013022882A2 true BR112013022882A2 (pt) | 2016-12-20 |
Family
ID=45894680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013022882A BR112013022882A2 (pt) | 2011-03-11 | 2012-03-12 | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140134170A1 (enExample) |
| EP (1) | EP2683741A2 (enExample) |
| JP (1) | JP2014508782A (enExample) |
| KR (1) | KR20140044796A (enExample) |
| CN (1) | CN103562226A (enExample) |
| AU (1) | AU2012229147B2 (enExample) |
| BR (1) | BR112013022882A2 (enExample) |
| CA (1) | CA2828075A1 (enExample) |
| EA (1) | EA201300996A1 (enExample) |
| MX (1) | MX2013010379A (enExample) |
| SG (1) | SG192844A1 (enExample) |
| WO (1) | WO2012125573A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2716301T1 (sl) | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in uporaba le-teh |
| DK2544680T3 (en) | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| US9527913B2 (en) | 2012-05-02 | 2016-12-27 | Symphogen A/S | Humanized pan-HER antibody compositions |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| ES2816624T3 (es) | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| RS66392B1 (sr) | 2014-02-28 | 2025-02-28 | Merus Nv | Antitelo koje vezuje erbb-2 i erbb-3 |
| CN111956653B (zh) | 2014-05-08 | 2023-06-30 | 上海市生物医药技术研究院 | 双炔失碳酯组合物和疾病治疗方法 |
| EA201792294A1 (ru) | 2015-04-17 | 2018-03-30 | Мерримак Фармасьютикалс, Инк. | Комбинированное лечение (варианты) с применением серибантумаба |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| ITUB20160828A1 (it) * | 2016-02-18 | 2017-08-18 | Univ Degli Studi Genova | Utilizzo di una dieta che mima il digiuno per potenziare l'efficacia di antiestrogeni nella terapia del cancro |
| BR112018068512A2 (pt) * | 2016-03-15 | 2019-01-22 | Merrimack Pharmaceuticals Inc | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 |
| SG10201913951YA (en) | 2016-10-11 | 2020-03-30 | Univ Duke | Lasofoxifene treatment of er+ breast cancer |
| JP6899504B2 (ja) * | 2017-01-10 | 2021-07-07 | ゼジアン ジャーチ デベロップメント ファーマシューティカルズ リミテッド | 膜開始エストロゲンシグナルのラソフォキシフェンでのモジュレーションおよび腫瘍の治療方法 |
| IL269656B2 (en) | 2017-03-31 | 2024-06-01 | Merus Nv | Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene |
| EP3625264B9 (en) * | 2017-05-17 | 2023-10-25 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
| US11497730B2 (en) | 2018-04-10 | 2022-11-15 | Duke University | Lasofoxifene treatment of breast cancer |
| TW202227504A (zh) * | 2020-10-15 | 2022-07-16 | 大陸商上海翰森生物醫藥科技有限公司 | 抗ｅｒｂｂ３抗體或其抗原結合片段及其醫藥用途 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5977322A (en) | 1995-06-14 | 1999-11-02 | The Regents Of The University Of California | High affinity human antibodies to tumor antigens |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7638302B2 (en) | 2001-05-31 | 2009-12-29 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| WO2003080835A1 (en) | 2002-03-26 | 2003-10-02 | Zensun (Shanghai) Sci-Tech. Ltd. | Erbb3 based methods and compositions for treating neoplasms |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| SI2716301T1 (sl) * | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in uporaba le-teh |
| AU2008221118B2 (en) | 2007-03-01 | 2013-10-03 | Les Laboratoires Servier | Recombinant anti-epidermal growth factor receptor antibody compositions |
| KR20100024410A (ko) | 2007-05-11 | 2010-03-05 | 엔즌 파마슈티칼스, 인코포레이티드 | Ｈｅｒ３ 조절용 ｒｎａ 길항제 화합물 |
| KR20110008086A (ko) * | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| NZ591137A (en) | 2008-08-15 | 2012-10-26 | Merrimack Pharmaceuticals Inc | Methods and systems for predicting response of cells to a therapeutic agent |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| WO2011047180A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| DK2544680T3 (en) * | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
| WO2011136911A2 (en) | 2010-04-09 | 2011-11-03 | Aveo Pharmaceuticals, Inc. | Anti-erbb3 antibodies |
| SG186889A1 (en) * | 2010-07-09 | 2013-02-28 | Exelixis Inc | Combinations of kinase inhibitors for the treatment of cancer |
-
2012
- 2012-03-12 CA CA2828075A patent/CA2828075A1/en not_active Abandoned
- 2012-03-12 BR BR112013022882A patent/BR112013022882A2/pt not_active IP Right Cessation
- 2012-03-12 AU AU2012229147A patent/AU2012229147B2/en not_active Ceased
- 2012-03-12 CN CN201280012969.XA patent/CN103562226A/zh active Pending
- 2012-03-12 US US14/004,598 patent/US20140134170A1/en not_active Abandoned
- 2012-03-12 WO PCT/US2012/028792 patent/WO2012125573A2/en not_active Ceased
- 2012-03-12 KR KR1020137026392A patent/KR20140044796A/ko not_active Withdrawn
- 2012-03-12 MX MX2013010379A patent/MX2013010379A/es unknown
- 2012-03-12 EA EA201300996A patent/EA201300996A1/ru unknown
- 2012-03-12 EP EP12711080.7A patent/EP2683741A2/en not_active Withdrawn
- 2012-03-12 SG SG2013062856A patent/SG192844A1/en unknown
- 2012-03-12 JP JP2013557943A patent/JP2014508782A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013010379A (es) | 2014-03-27 |
| CN103562226A (zh) | 2014-02-05 |
| WO2012125573A2 (en) | 2012-09-20 |
| AU2012229147A1 (en) | 2013-03-14 |
| EA201300996A1 (ru) | 2014-01-30 |
| JP2014508782A (ja) | 2014-04-10 |
| SG192844A1 (en) | 2013-09-30 |
| AU2012229147B2 (en) | 2015-12-24 |
| WO2012125573A3 (en) | 2012-12-27 |
| KR20140044796A (ko) | 2014-04-15 |
| NZ614427A (en) | 2015-08-28 |
| US20140134170A1 (en) | 2014-05-15 |
| EP2683741A2 (en) | 2014-01-15 |
| CA2828075A1 (en) | 2012-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013022882A2 (pt) | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários | |
| HUS2100049I1 (hu) | Rákok kezelése PI3 kináz izoform modulátorok alkalmazásával | |
| IL272206B (en) | Combination therapy for treating cancer | |
| PL2768493T3 (pl) | Fitokannabinoidy do stosowania w leczeniu raka piersi | |
| PL3074035T3 (pl) | Kompozycje zawierające przeciwciała anty-CEACAM1 i anty-PD do terapii raka | |
| MX2016002974A (es) | Eteres de arilo y sus usos. | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| PL3023788T3 (pl) | Kompozycje neoantygenów specyficznych wobec nowotworu do zastosowania w leczeniu nowotworów | |
| IL239007B (en) | Eribulin for use in the treatment of breast cancer | |
| HRP20220897T8 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| BR112014009755A2 (pt) | tratamento de câncer com inibidores de quinase tor | |
| BR112013024248A2 (pt) | medidor de semente | |
| HUE057061T2 (hu) | Kombinációs terápia rák kezelésére | |
| IL225441A0 (en) | Breast cancer diagnostics | |
| BR112013024211A2 (pt) | tratamento de tumores sólidos | |
| HRP20190046T1 (hr) | Kombinirana terapija za liječenje raka | |
| BR112013028039A2 (pt) | composição de cimento | |
| BR112013025866A2 (pt) | formulações com viscosidade reduzida | |
| BR112013022438A2 (pt) | forma de dosagem de dietilestilbestrol e uso para tratamento de câncer de próstota ou de mama | |
| EA201890598A3 (ru) | Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты | |
| IL231757A (en) | Antagonists ras for the treatment of malignant and non-malignant diseases | |
| HUE045445T2 (hu) | Kombinált terápia petefészekrák kezelésére | |
| HRP20180685T1 (hr) | Antitijelo protiv humanog dlk-1 koje posjeduje protutumorsko djelovanje in vivo | |
| DK2802351T3 (da) | Midler til behandling af triple-negativ brystkræft | |
| EP2925361A4 (en) | COMBINATION THERAPY FOR THE TREATMENT OF HER2-POSITIVE CARCINOMA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |